| You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please unsubscribe here. Dear Fellow Investor, On December 13, 2022, a Big Pharma giant quietly bought one AI-designed drug for $4 billion.
That makes it the biggest deal for an AI-designed drug in history.
But very few people even know about it...yet.
Even leading investors in the U.S. have no idea.
And they don't know that this tiny AI-biotech designed the drug.
But this won't stay quiet much longer.
On January 9, 2023, Bristol Myers Squibb signed a $2.7 billion deal to have their AI-platform develop six new drugs.
On October 6, 2022, Eli Lilly signed a $425 million deal to have their AI-platform develop a new drug.
These seven drugs alone could bring $28 billion to this little-known company.
That doesn't include deals they signed with Sanofi, Nimbus Therapeutics, Petra Pharma and others.
Wall Street doesn't yet grasp how this company is quietly revolutionizing the drug discovery business...
Which is why I believe this will be the biggest AI winner you never heard of.
Get the name of the stock here...while it's still a small-cap >>> |
| Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
Behind the Markets
Unsubscribe
|
|
